

AMENDMENTS TO THE CLAIMS

Claim Listing:

1. (currently amended) A method of treating a human body for cancer comprising administering an effective therapeutic amount of doxorubicin, in combination with ET-743 in a dose range between about 0.5 and 4.2 about 0.75 mg/m² for ET-743, and of about 50 mg/m² or about 60 mg/m² for doxorubicin.
2. (canceled)
3. (currently amended) The method according to claim 1 ~~or 2~~, wherein doxorubicin and ET-743 are provided as separate medicaments for administration at different times.
4. (original) The method according to claim 3, wherein doxorubicin is administered prior to the administration of ET-743.
5. (original) The method according to claim 4, wherein doxorubicin and ET-743 are administered by intravenous injection.
6. (original) The method according to claim 5, wherein the infusion time for intravenous injection is up to 3 hours for doxorubicin and up to 24 hours for ET-743.
7. (original) The method according to claim 6, wherein the infusion time for intravenous injection is about 1 hour for doxorubicin and about 3 hours for ET-743.

8. (original) The method according to claim 7, where the infusions are carried out at an interval of 1 to 6 weeks.

9. (original) The method according to claim 8, wherein the infusions of both drugs are carried out once every 21 days.

10. (currently amended) The method according to claim 6 ~~claim 8~~, wherein the infusion of doxorubicin is carried out on day 1 and the infusion of ET-743 on days 1 and 8, every 21 days.

11. (canceled)

12. (currently amended) The method according to claim 9 ~~claim 11~~, wherein doxorubicin is administered in a dosage about 60 mg/m^2 , followed by ET-743 which is administered in a dosage about 0.7 mg/m^2 .

13. (currently amended) The method according to claim 10 ~~claim 11~~, wherein doxorubicin is administered in a dosage about 50 mg/m^2 , followed by ET-743 which is administered in a dosage about 0.6 mg/m^2 .

14. (previously presented) A method according to claim 1, in which the patient has a cancer selected from sarcoma, osteosarcoma, ovarian cancer, breast cancer, melanoma, colorectal cancer, mesothelioma, renal cancer, endometrial cancer and lung cancer.

15. (original) A method according to claim 14, in which the patient has a cancer selected from sarcoma, ovarian cancer, endometrial cancer and breast cancer.

16-19. (canceled)